Tazemetostat: all 41 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal CarcinomaNot yet recruitingNCT05151588Phase 2
- Tazemetostat in Malignant Peripheral Nerve Sheath TumorsActive, not recruitingNCT04917042Phase 2Results posted
- SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular LymphomaTerminatedNCT04762160Phase 2Results posted
- A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate CancerTerminatedNCT04179864Phase 1/2Results posted
- Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene MutationCompletedNCT03456726Phase 2Results posted
- Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial CancerActive, not recruitingNCT03348631Phase 2Results posted
- Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213665Phase 2Results posted
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
- Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor PatientsCompletedNCT03028103Phase 1Results posted
- A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT03009344Phase 1Results posted
- Study of the EZH2 Inhibitor Tazemetostat in Malignant MesotheliomaCompletedNCT02860286Phase 2Results posted
- A Study of Tazemetostat in Adult Participants With Soft Tissue SarcomaCompletedNCT02601950Phase 2Results posted
- EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial SarcomaCompletedNCT02601937Phase 1Results posted
- Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular LymphomaSuspendedNCT06575686Phase 2
- Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT06242834Phase 2
- A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic MutationWithdrawnNCT06068881Phase 2
- Study of Tazemetostat in Lymphoid MalignanciesTerminatedNCT05983965Phase 1
- A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell LymphomasActive, not recruitingNCT05934838Phase 1
- A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory LymphomaCompletedNCT05713110Phase 2
- Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted TreatmentActive, not recruitingNCT05627245Phase 1
- Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin LymphomaTerminatedNCT05618366Phase 1
- Zandelisib + Tazemetostat in R/R Follicular LymphomaWithdrawnNCT05604417Phase 1/2
- A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate CancerWithdrawnNCT05567679Early Phase 1
- A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular LymphomaActive, not recruitingNCT05551936Phase 1/2
- Tazemetostat for the Treatment of Relapsed/Refractory Follicular LymphomaCompletedNCT05467943Phase 2
- Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsActive, not recruitingNCT05407441Phase 1/2
- Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular LymphomaWithdrawnNCT05152459Phase 1/2
- Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A MutationTerminatedNCT05023655Phase 2
- Tazemetostat for the Treatment of Moderate to Severe COVID-19 InfectionWithdrawnNCT05018975Phase 2
- Phase Ia/Ib Talazoparib + Tazemetostat for mCRPCActive, not recruitingNCT04846478Phase 1
- Combining Epigenetic And Immune Therapy to Beat Cancer.CompletedNCT04705818Phase 2
- Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaTerminatedNCT04624113Phase 1
- A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver FunctionTerminatedNCT04241835Phase 1
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.Active, not recruitingNCT04224493Phase 3
- Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid SarcomaTerminatedNCT04204941Phase 1
- Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial CarcinomaActive, not recruitingNCT03854474Phase 1/2
- Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver DysfunctionWithdrawnNCT03217253Phase 1
- Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid TumorsCompletedNCT03010982Phase 1
- Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by ChemiotherapyActive, not recruitingNCT02889523Phase 1/2
- A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical StudyCompletedNCT02875548Phase 1/2
- A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaCompletedNCT02220842Phase 1